2m 2m 2m 2m 2m 2m 2m
- $477.0MMarket Cap
- 66.03%1-Year Change
- Health Information ServicesIndustry
SOPHIA GENETICS N (SOPH)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 62
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
U.S. stock futures showed mixed performance on Wednesday with the Dow Jones declining while the S&P 500 and Nasdaq 100 advanced. Investors awaited the FOMC interest rate decision expected at 2:00 p.m. ET, with markets pricing a 99.6% likelihood of unchanged rates. Notable movers included La-Z-Boy surging 19.62% on strong earnings and a $300 million buyback, Amkor jumping 5.49% after signing a 10-year deal with TSMC, and SpaceX rising 3.22% following its Cursor AI acquisition.
06/17/2026, 8:44 AM • Benzinga
U.S. stock futures showed mixed performance on Wednesday with the Dow Jones declining while the S&P 500 and Nasdaq 100 advanced. Investors awaited the FOMC interest rate decision expected at 2:00 p.m. ET, with markets pricing a 99.6% likelihood of unchanged rates. Notable movers included La-Z-Boy surging 19.62% on strong earnings and a $300 million buyback, Amkor jumping 5.49% after signing a 10-year deal with TSMC, and SpaceX rising 3.22% following its Cursor AI acquisition.
06/17/2026, 5:29 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Key Executives
- Jurgi Camblong
- Manuela Da Silva Valente
- Ross Jordan Muken
- Kellen Sanger
- Kevin Puylaert
Current Ownership Distribution
- Institutions347.9M (74.53%)
- Mutual Funds111.7M (23.93%)
- Insiders7.2M (1.54%)
- Other0 (0.00%)